Company Profile
Sarepta Therapeutics Stock Price, News & Analysis
- Ticker:
- SRPT
- Exchange:
- NASDAQ
- Sector:
- Gene Therapy
- Location:
- United States
Stock performance
16.78 USD (+5.34%)
Close
Last updated: August 6, 2026
1.72B USD
Market cap
Why the stock is moving
Following the latest company update, “Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments”, SRPT closed up 5.34% at $16.78 on Aug 6, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Precision Genetic Medicine
Sarepta Therapeutics develops and commercializes genetic medicines for rare neuromuscular diseases, with a major focus on Duchenne muscular dystrophy.
ELEVIDYS
ELEVIDYS is an AAV-based gene-transfer therapy that delivers a micro-dystrophin transgene to skeletal muscle. It is indicated for ambulatory patients aged four years and older with confirmed Duchenne mutations.
Exon-Skipping Franchise
EXONDYS 51, VYONDYS 53 and AMONDYS 45 use phosphorodiamidate morpholino oligomers to skip specific dystrophin exons in genetically eligible Duchenne patients.
siRNA Platform
SRP-1001 and SRP-1003 are integrin-targeted siRNA candidates in Phase 1/2 development for facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1.
Global Commercial Partnerships
Sarepta commercializes directly in the United States and works with Roche and Chugai on ELEVIDYS outside the U.S., combining internal development with regional partnerships.
Future catalysts
Sarepta’s key catalyst window is still Elevidys, including regulatory / safety scrutiny, plus any DMD pipeline update that can stabilize the story. The next checkpoint matters because it tells investors whether the program is still moving on schedule or whether the timeline needs to be reset. A clean outcome also makes it easier to think about the next regulatory or label step instead of just the current filing.
Recent news
- 01
Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments
Source: Sarepta Therapeutics
- 02
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: Sarepta Therapeutics
- 03
Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer
Source: Sarepta Therapeutics
- 04
Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results
Source: Sarepta Therapeutics
- 05
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®
Source: Sarepta Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Sarepta Therapeutics (SRPT)?
Sarepta Therapeutics (SRPT) most recently closed at 16.78 USD, a +5.34% move versus the previous session.
What is the market cap of Sarepta Therapeutics (SRPT)?
Sarepta Therapeutics currently has a market capitalization of 1.72B USD on BioPharmSignal.
What does Sarepta Therapeutics do?
Precision Genetic Medicine Sarepta Therapeutics develops and commercializes genetic medicines for rare neuromuscular diseases, with a major focus on Duchenne muscular dystrophy. ELEVIDYS ELEVIDYS is an AAV-based gene-transfer therapy that delivers a micro-dystrophin transgene to skeletal muscle. It is indicated for ambulatory patients aged four years and...
On which exchange is SRPT stock listed?
Sarepta Therapeutics (SRPT) is associated with NASDAQ, United States, Gene Therapy.
What is SRP-1001?
siRNA Platform SRP-1001 and SRP-1003 are integrin-targeted siRNA candidates in Phase 1/2 development for facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1.
Which conditions is Sarepta Therapeutics targeting with SRP-1001?
Sarepta Therapeutics is associated with genetic disease based on its company overview and current catalyst commentary.
How does Sarepta Therapeutics describe recent progress with SRP-1001?
Sarepta’s key catalyst window is still Elevidys, including regulatory / safety scrutiny, plus any DMD pipeline update that can stabilize the story. The next checkpoint matters because it tells investors whether the program is still moving on schedule or whether the timeline needs to be reset. A clean outcome also makes it easier to think about the next...
What is SRP-1003?
siRNA Platform SRP-1001 and SRP-1003 are integrin-targeted siRNA candidates in Phase 1/2 development for facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1.